3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
62
Carcinoma, Hepatocellular
25
Neoplasm Metastasis
15
Rectal Neoplasms
11
Colonic Neoplasms
10
Gastrointestinal Stromal Tumors
9
Sarcoma
6
Ovarian Neoplasms
5
Osteosarcoma
5
Glioblastoma
5
Cholangiocarcinoma
5
Stomach Neoplasms
4
Melanoma
4
Liver Neoplasms
4
Sarcoma, Ewing
3
Pancreatic Neoplasms
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Esophageal Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Neoplasms
2
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
30
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Paclitaxel
13
Gemcitabine
13
apatinib
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
9
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
regorafenib
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn